For more than a decade, access to the meningitis B vaccine in England depended heavily on date of birth. The national MenB programme began in September 2015 for babies, accompanied by a limited catch-up for infants due their three- and four-month vaccinations that September. Children just outside that window were not offered the same routine protection.
A March 2026 Guardian letter put a family's experience behind the cutoff. Aimée Hamblin wrote that her son, born in December 2014, was ineligible while younger children could receive the vaccine through the NHS. Her family paid privately. She argued that other families might not have known about the option or been able to afford it.
That account supports a clear access problem, but it does not establish national private-vaccine prices, uptake rates or the size of a hypothetical catch-up bill. Those figures were not documented by the reviewed sources and should not be used to turn a real eligibility gap into a false statistical case.
The 2015 Programme Created a Defined Boundary
The Department of Health and Social Care's original announcement said babies aged two months would be offered MenB vaccination from September 2015, followed by another dose at four months and a booster at 12 months. The catch-up was deliberately limited to infants reaching specified vaccination ages at the programme's launch.
The programme targeted the age group then considered at greatest risk. It did not create routine MenB coverage for the older children and teenagers who had already passed infancy. MenACWY vaccination, offered to teenagers, protects against meningococcal groups A, C, W and Y; it is not a substitute for MenB vaccination.
The consequences of that distinction became more visible during the March 2026 MenB outbreak in Kent. The outbreak prompted a targeted response and a government request for the Joint Committee on Vaccination and Immunisation to reassess vaccination in older children and young adults.
A Limited 2026 Offer Changed Immediate Access
On 12 June, the government announced a one-off, time-limited MenB programme in response to recent outbreaks. NHS guidance reviewed on 14 July says that 17- and 18-year-olds born between 1 September 2007 and 31 August 2008 can book in England. It also covers eligible people under 25 entering university or some residential further-education colleges for the first time in autumn 2026.
The NHS specifies two doses at least four weeks apart. UK Health Security Agency guidance says protection takes a further two weeks to build after the second dose and advises eligible students to start before the autumn term where possible.
This offer is broader than the old infant-only route, but it is not a universal catch-up for everyone excluded by the 2015 cutoff. UKHSA describes it as a focused programme for groups at highest immediate risk. People outside its eligibility rules may still face private access if they seek vaccination.
JCVI Has Now Backed Adolescent Vaccination
JCVI's 16 July statement goes further. It recommends a routine 4CMenB offer at around age 15 for adolescents born on or after 1 May 2015 who were eligible in infancy. Those in that group who missed infant vaccination should receive two doses.
The committee also addressed the older, unvaccinated cohort directly. It strongly supports offering two doses to adolescents born on or before 30 April 2015 and an additional catch-up for people who could otherwise fall between the temporary 2026 offer and a future routine programme. JCVI framed that support in part as an equity issue, while acknowledging uncertainty in the cost-effectiveness calculation for unprimed adolescents.
The evidence is not a promise of complete protection. JCVI reported vaccine effectiveness of about 82.9% against all MenB strains and reductions in cases for at least six years after infant vaccination. It also said adolescent vaccination does not prevent meningococcal carriage, so it is expected to provide direct protection rather than herd protection.
The Gap Is Smaller, Not Yet Closed
The policy debate has changed substantially since the original family complaint. England now has a temporary offer for selected older students, and the government's vaccine advisers have recommended a lasting adolescent programme plus catch-up coverage for those missed in infancy.
The hard test is implementation. A recommendation can correct the logic of a birth-date cutoff, but it cannot book an appointment, fund a national programme or guarantee equal access. Until ministers publish and deliver a schedule that reaches the unvaccinated cohort, the old gap has been acknowledged rather than fully closed.